ASCO® 2023 Insights: "STAR-221 Phase 3 Trial - Domvanalimab, Zimberelimab, & Chemo vs. Nivo & Chemo in Previously Untreated, Locally Advanced, Unresectable or Metastatic GC/GEJC/EC"

235 views
June 15, 2023
0 Comments
Login to view comments. Click here to Login